Effects of JNJ-54452840, an Anti-β1 Receptor Antibody Cyclopeptide in Heart Failure Patients: A Randomized, Double-blind, Parallel-group, Phase-2 Pilot Study

Stefan Störk^1*, Alexei N Plotnikov², Gary Peters², Brian E Davies², Ivo Nnane², David Rivas², Fisseha Tesfaye², Stefan Kääb^3,4, Axel Bauer³, Andreas Luchner⁵, Martin Ungerer⁶, Roland Jahns^1,7, Martin Lohse^1,8 and Georg Ertl¹

¹Comprehensive Heart Failure Center (CHFC), University of Würzburg, Germany

²Janssen Research and Development, LLC, New Jersey, USA

³Department of Medicine I–Cardiology, Ludwig-Maximillian’s University Hospital, Munich, Germany

⁴DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

⁵Department of Internal Medicine III - Cardiology, University of Tubingen, Germany

⁶AdvanceCor GmbH (formerly Procorde), Martinsried, Germany

⁷CHFC and Interdisciplinary Bank of Biomaterials and Data Würzburg, University Hospital of Würzburg, Germany

⁸Rudolf Virchow Center / DFG Research Center for Experimental Biomedicine, Würzburg, Germany

^*Corresponding Author: